Clinical Trials · NCT05493709

Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

Name: Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Gonadorelin

Phase: Phase 3
Recruitment status: Completed
Sponsor: Foresee Pharmaceuticals Co., Ltd.
Enrollment: 94
Start date: Jun 2023
Locations: 41 sites, 4 countries
Primary endpoint: Efficacy of Leuprolide Mesylate (FP-001 42 mg)

View Gonadorelin compound reference